Accellix, Inc. and Streck Collaborate to Advance Cell Therapy with Quality Control
24.9.2025 15:00:00 EEST | Business Wire | Press release
Accellix™, a pioneer in automated flow cytometry, and Streck, a recognized leader in quality control materials for flow cytometry, hematology and molecular diagnostics, have announced a strategic collaboration with the addition of the Accellix Automated Cell Phenotyping Platform to Streck’s CD-Chex Plus® (RUO) control.
The Accellix platform is a compact, fully automated flow cytometer designed for point-of-need environments. It uses single-use, microfluidic cartridges to automate the entire cell phenotyping process, from antibody staining to flow cytometry acquisition and data analysis. This enables rapid, reproducible results without the need for complex instrumentation or specialized operators.
By integrating CD-Chex Plus (RUO) control into the Accellix workflow, users can assess the Accellix platform performance and ensure reliable operation. This addition supports routine monitoring and helps users maintain trust in their data without introducing complexity or requiring a separate or centralized lab infrastructure.
“This collaboration reflects our commitment to helping cell therapy developers and labs worldwide achieve faster, more reliable results. By aligning with Streck and CD-Chex Plus (RUO) control, we’re making it easier to simplify flow cytometry quality control across a multitude of instruments, locations and environments utilizing the Accellix technology,” said Rey Mali, Chief Operations Officer at Accellix.
“We’re excited to work with a team that shares our mission to support laboratories and companies with reliable, streamlined solutions that enable positive outcomes in health care,” said Matt Thummel, Director of Business Segment – Hematology, Body Fluids and Flow Cytometry at Streck. “Adding the Accellix platform to the CD-Chex Plus (RUO) control gives platform users a dependable way to monitor performance and maintain confidence in their results, especially in fast-paced manufacturing environments.”
The Accellix Automated Cell Phenotyping Platform will be added to the CD-Chex Plus (RUO) control with lot 5265, shipping September 22, 2025.
CD-Chex Plus (RUO) is For Research Use Only. Not for use in diagnostic procedures.
About Accellix, Inc.
Accellix is a biotechnology company dedicated to developing and commercializing the Accellix Platform to enable its customers in the fields of cell and gene therapy and blood characterization to meet their critical QC requirements as they advance life-changing therapies benefiting patients worldwide. Accellix empowers its customers by migrating their existing cell phenotyping assays to the Accellix Platform. The Accellix Platform is a benchtop cytometer operating and reading capillary cartridges integrated with dry reagents. It provides unmatched reproducibility and ease of use for automated multi-parametric cell analysis. For more information, visit www.accellix.com.
About Streck, Inc.
Established in 1971, Streck provides solutions that ensure every result counts by empowering clinical and research laboratories to reliably deliver accurate results, advance diagnostics and enable healthier, happier lives for patients everywhere. Streck products are manufactured in La Vista, Nebraska, and delivered to thousands of labs worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250924981154/en/
Contacts
info@accellix.com
hello@streck.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Publishes Inaugural Taskforce on Nature-related Financial Disclosures Report22.9.2026 12:00:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today published its inaugural Taskforce on Nature-related Financial Disclosures (TNFD) Report, providing shareholders and other stakeholders with its most comprehensive assessment to date of nature-related dependencies, impacts, risks, and opportunities (DIROs) across the company’s global value chain. As an early adopter of the TNFD recommendations, PMI’s TNFD Report supports the company’s efforts to sharpen its understanding of how natural capital considerations influence business resilience and decision-making over time, while contributing to emerging practices in nature-related disclosure. Nature is one of the six strategic priorities that define PMI’s Value Plan 2030+, the company’s framework for long-term sustainable value creation, alongside Consumers, Circularity, Climate, Our Workforce, Workers in Our Value Chain. The TNFD Report follows the release of PMI’s 2025 Climate Transition Plan, prepared in line with the TCFD framework,
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 10:00:00 EEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 09:33:00 EEST | Press release
Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embedding AI in operations, and only 13% report no current plan. The constraint is a shared one. Embedded, production-level use sits between 8% and 15% at every institution tier, and 16% of respondents overall have reached it, with 89% of financial institutions yet to get there. Resources buy experimentation, but production use is earned on the same terms
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 2028 1 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements: Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 08:00:00 EEST | Press release
OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of 96% over each program’s original media combinations*. In separate internal studies, OPM-CHO media demonstrated lot-to-lot variability below 5%.* As patent expirations create new opportunities for biosimilar development, achieving a pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom